Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents. Academic Article uri icon

abstract

  • The 2,4-diaminoquinazoline class of compounds has previously been identified as an effective inhibitor of Mycobacterium tuberculosis growth. We conducted an extensive evaluation of the series for its potential as a lead candidate for tuberculosis drug discovery. Three segments of the representative molecule N-(4-fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine were examined systematically to explore structure-activity relationships influencing potency. We determined that the benzylic amine at the 4-position, the piperidine at 2-position and the N-1 (but not N-3) are key activity determinants. The 3-deaza analog retained similar activity to the parent molecule. Biological activity was not dependent on iron or carbon source availability. We demonstrated through pharmacokinetic studies in rats that good in vivo compound exposure is achievable. A representative compound demonstrated bactericidal activity against both replicating and non-replicating M. tuberculosis. We isolated and sequenced M. tuberculosis mutants resistant to this compound and observed mutations in Rv3161c, a gene predicted to encode a dioxygenase, suggesting that the compound may act as a pro-drug.

published proceedings

  • Bioorg Med Chem

altmetric score

  • 7.25

author list (cited authors)

  • Odingo, J., O'Malley, T., Kesicki, E. A., Alling, T., Bailey, M. A., Early, J., ... Parish, T.

citation count

  • 23

complete list of authors

  • Odingo, Joshua||O'Malley, Theresa||Kesicki, Edward A||Alling, Torey||Bailey, Mai Ann||Early, Julie||Ollinger, Juliane||Dalai, Suryakanta||Kumar, Naresh||Singh, Ravindra Vikram||Hipskind, Philip A||Cramer, Jeffrey W||Ioerger, Thomas||Sacchettini, James||Vickers, Richard||Parish, Tanya

publication date

  • December 2014